FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311692020> ?p ?o ?g. }

• W4311692020 abstract "Abstract Objectives The identification of novel uses for existing drug therapies has the potential to provide a rapid, low-cost approach to drug (re)discovery. In the current study we developed and tested a genetically-informed drug-repurposing pipeline for diabetes management. Design We developed and tested a genetically-informed drug-repurposing pipeline for diabetes management. This approach mapped genetically predicted gene expression signals from the largest genome-wide association study for type 2 diabetes mellitus to drug targets using publicly available databases to identify drug-gene pairs. These drug-gene pairs were then validated using a two-step approach: 1) a self-controlled case-series (SCCS) using electronic health records from a discovery and replication population, and 2) Mendelian randomization (MR). Setting The SCCS experiments were completed using two EHRs: the Million Veterans Program (USA) as the discovery and the Vanderbilt University Medical Center (Tennessee, USA) as the replication. Results After filtering on sample size, 20 candidate drug-gene pairs were validated and various medications demonstrated evidence of glycemic regulation including two anti-hypertensive classes: angiotensin-converting enzyme inhibitors as well as calcium channel blockers (CCBs). The CCBs demonstrated the strongest evidence of glycemic reduction in both validation approaches (SCCS HbA1c and glucose reduction: -0.11%, p=0.01 and -0.85 mg/dL, p=0.02, respectively; MR: OR=0.84, 95% CI=0.81, 0.87, p=5.0×10-25). Conclusions Our results support CCBs as a strong candidate medication for blood glucose reduction in addition to cardiovascular disease reduction. Further, these results support the adaptation of this approach for use in future drug-repurposing efforts for other conditions. Summary Boxes Section 1: What is already known on this topic Medications with genetic support are significantly more likely to make it through clinical trials. Section 2: What this study adds Our results identified two anti-hypertensive medication classes, calcium channel blockers and angiotensin-converting enzyme inhibitors, as genetically supported drug-repurposing targets that demonstrated glycemic measurement reduction in real-world clinical populations. These results suggest patients with diabetes or pre-diabetes could benefit from preferential use of these medication classes when they present with comorbid hypertension or other cardiovascular conditions. Finally, this study demonstrates a successful implementation of a novel genetically-supported drug-repurposing pipeline for diabetes treatment that can be readily adapted and applied to other diseases and as such it has the potential to identify/prioritize drug repurposing targets for these other conditions." @default.
• W4311692020 created "2022-12-28" @default.
• W4311692020 creator A5004289607 @default.
• W4311692020 creator A5007930206 @default.
• W4311692020 creator A5027729792 @default.
• W4311692020 creator A5045336623 @default.
• W4311692020 creator A5046612794 @default.
• W4311692020 creator A5048214696 @default.
• W4311692020 creator A5060149257 @default.
• W4311692020 creator A5066907464 @default.
• W4311692020 creator A5082565112 @default.
• W4311692020 creator A5088127847 @default.
• W4311692020 creator A5091613665 @default.
• W4311692020 creator A5091631434 @default.
• W4311692020 date "2022-12-16" @default.
• W4311692020 modified "2023-10-15" @default.
• W4311692020 title "A genetically supported drug repurposing pipeline for diabetes treatment using electronic health records" @default.
• W4311692020 cites W1516041857 @default.
• W4311692020 cites W1967553740 @default.
• W4311692020 cites W1967724716 @default.
• W4311692020 cites W1982945330 @default.
• W4311692020 cites W1989590412 @default.
• W4311692020 cites W1993323719 @default.
• W4311692020 cites W2006776184 @default.
• W4311692020 cites W2023984564 @default.
• W4311692020 cites W2044437167 @default.
• W4311692020 cites W2062941476 @default.
• W4311692020 cites W2063639355 @default.
• W4311692020 cites W2096541451 @default.
• W4311692020 cites W2113699335 @default.
• W4311692020 cites W2116145810 @default.
• W4311692020 cites W2126838326 @default.
• W4311692020 cites W2130189158 @default.
• W4311692020 cites W2139562487 @default.
• W4311692020 cites W2141432783 @default.
• W4311692020 cites W2146264128 @default.
• W4311692020 cites W2152289419 @default.
• W4311692020 cites W2159636537 @default.
• W4311692020 cites W2238851414 @default.
• W4311692020 cites W2239799525 @default.
• W4311692020 cites W2465667391 @default.
• W4311692020 cites W2493860075 @default.
• W4311692020 cites W2620668688 @default.
• W4311692020 cites W2735404270 @default.
• W4311692020 cites W2805983714 @default.
• W4311692020 cites W2884743521 @default.
• W4311692020 cites W2895533920 @default.
• W4311692020 cites W2896002881 @default.
• W4311692020 cites W2899349918 @default.
• W4311692020 cites W2903782905 @default.
• W4311692020 cites W2904891280 @default.
• W4311692020 cites W2924479779 @default.
• W4311692020 cites W2950099124 @default.
• W4311692020 cites W2950439954 @default.
• W4311692020 cites W2951276412 @default.
• W4311692020 cites W2951435941 @default.
• W4311692020 cites W2955247325 @default.
• W4311692020 cites W2972869264 @default.
• W4311692020 cites W2990212836 @default.
• W4311692020 cites W3030577746 @default.
• W4311692020 cites W3035152464 @default.
• W4311692020 cites W4210426420 @default.
• W4311692020 cites W4210703904 @default.
• W4311692020 cites W4225092399 @default.
• W4311692020 cites W4237332786 @default.
• W4311692020 doi "https://doi.org/10.1101/2022.12.14.22283414" @default.
• W4311692020 hasPublicationYear "2022" @default.
• W4311692020 type Work @default.
• W4311692020 citedByCount "0" @default.
• W4311692020 crossrefType "posted-content" @default.
• W4311692020 hasAuthorship W4311692020A5004289607 @default.
• W4311692020 hasAuthorship W4311692020A5007930206 @default.
• W4311692020 hasAuthorship W4311692020A5027729792 @default.
• W4311692020 hasAuthorship W4311692020A5045336623 @default.
• W4311692020 hasAuthorship W4311692020A5046612794 @default.
• W4311692020 hasAuthorship W4311692020A5048214696 @default.
• W4311692020 hasAuthorship W4311692020A5060149257 @default.
• W4311692020 hasAuthorship W4311692020A5066907464 @default.
• W4311692020 hasAuthorship W4311692020A5082565112 @default.
• W4311692020 hasAuthorship W4311692020A5088127847 @default.
• W4311692020 hasAuthorship W4311692020A5091613665 @default.
• W4311692020 hasAuthorship W4311692020A5091631434 @default.
• W4311692020 hasBestOaLocation W43116920201 @default.
• W4311692020 hasConcept C103637391 @default.
• W4311692020 hasConcept C126322002 @default.
• W4311692020 hasConcept C134018914 @default.
• W4311692020 hasConcept C18903297 @default.
• W4311692020 hasConcept C2777180221 @default.
• W4311692020 hasConcept C2780035454 @default.
• W4311692020 hasConcept C2780473172 @default.
• W4311692020 hasConcept C519536355 @default.
• W4311692020 hasConcept C555293320 @default.
• W4311692020 hasConcept C60644358 @default.
• W4311692020 hasConcept C71924100 @default.
• W4311692020 hasConcept C86803240 @default.
• W4311692020 hasConcept C98274493 @default.
• W4311692020 hasConceptScore W4311692020C103637391 @default.
• W4311692020 hasConceptScore W4311692020C126322002 @default.
• W4311692020 hasConceptScore W4311692020C134018914 @default.
• W4311692020 hasConceptScore W4311692020C18903297 @default.

• next